Study Shows Aducanumab Improves Treatment Status and Rehabilitates Impaired TIM in Mice, Offering Promising Therapeutic Target for Alzheimer’s
Exhausted immune cells in the brain, “TIM (terminal inflammatory microglia)” Aducanumab improves treatment status and rehabilitates impaired TIM in mice “TIM may be a promising therapeutic target.” “It could lead to a new treatment for Alzheimer’s.” A study recently published in the medical journal Immunity found that “depleted” immune cells in the brain can cause […]
Examining CDR-SB Score Changes: Assessing Clinical Impact in Alzheimer’s Treatment
– Focus on CDR-SB score changes – Can these score changes be felt clinically? Provided by: Biogen homepage capture In 1906, Alois Alzheimer reported the first patient with Alzheimer’s disease, marking the beginning of our understanding of this devastating condition. Over the years, several drugs have been developed to alleviate the clinical symptoms associated with […]
Alzheimer’s treatment ‘Rechembi’ is on the verge of full approval… Is it possible to fundamentally cure dementia?
Rechembi, jointly developed with Biogen and Eisai, received a recommendation for official approval from the US FDA In phase 3 clinical trials, mild progression and cognitive decline were delayed by 27% compared to placebo It is expected to be the latest treatment that targets and affects the underlying mechanism of Alzheimer’s disease Rechembi global sales […]
